About Us

Established in 2012, Mensia Technologies has brought neurofeedback into the 21st century. In 2015, Mensia Technologies won a prestigious EU Horizon 2020 grant for Newrofeed, the non inferiority study comparing reference drug methylphenidate/RITALIN with Mensia Koala in the treatment of ADHD. Mensia aims to obtain the CE mark for Mensia Koala in the course of 2017.

Our Values

Cure Your Brain Without Drugs

Efficacy

We’re conducting the largest randomized controlled neurofeedback trial ever undertaken in ADHD comparing neurofeedback with methylphenidate. Results are expected by the end of 2017.

Patient Respect

We’ve developed a non-invasive therapy that — alone or in tandem with psychotropic drugs — holds enormous promise for patients, their families, physicians, and payers.

Team Work

Mensia’s success is built on a multidisciplinary approach, combining science, clinical development, and commercialization expertise.

Our Team

Jean-Yves Quentel

Co-founder & CEO

Jean Yves has 25 years of experience as an investor in, and as an adviser and manager of, technology companies in the US and Europe.

Michel du Peloux

Chief Operating Officer

Michel has 30 years of experience in leadership positions in pharmaceutical, medical device, and healthcare companies such as Merck CHC, Mérieux, Novartis, and Audika. Michel is also MD MBA.

Louis Mayaud

Chief Scientific Officer

Louis is an expert in brain-computer interface research. He holds a PhD from the University Oxford, and was project leader at Paris Hospital Trust, the largest hospital system in Europe, as project leader for using brain-computer interfaces to communicate with Locked In Syndrome patients. Louis is also PhD.

Benoît Perrin

V.P Engineering

Benoît is an experienced technology professional. He studied at École Polytechnique (Paris), and Imperial College London. Before joining Mensia, he held technology and management positions at a number of software and Web companies.

Our Board

Jean-Yves Quentel

Chairman Of The Board

Jean Yves has 25 years of experience as an investor in, and as an adviser and manager of, technology companies in the US and Europe.

Michel du Peloux

Board Member

Michel has 30 years of experience in leadership positions in pharmaceutical, medical device, and healthcare companies such as Merck CHC, Mérieux, Novartis, and Audika. Michel is also MD MBA.

Chahram Becharat

Board Member

Chahram is the former CEO of Damavand Mineral Waters in Iran where he is now a board member. Prior to that he was at LVMH as Senior Vice President, Selective Distribution Group, Director of DFS Group, Director of Sephora Group, and as Assistant to Bernard Arnault advising on acquisitions, investments and emerging market strategy. He was Senior Managing Director of Europ@web from 1999 to December 2001.

Pierre Saint Girons

Board Member

Pierre is an executive and entrepreneur in the medical device industry with experience in cardiology, neurology, orthopedics, and telemedicine. His past experience includes strategy definition, product portfolio development, business development and operational management in France, Scandinavia and Eastern Europe.

Laurent Kott

Board Member

Laurent is Chairman of IT-Translation, a seed-stage venture fund set up jointly by BPIFrance, France’s sovereign fund, and Inria, the only public research body fully dedicated to computational sciences in France. Prior to IT-Translation, Laurent was at Inria as Deputy General Manager, Head of Technology Transfer, and Head of Inria-Transfert.

Anatole Lecuyer

Scientific Advisor

Anatole is Director of Research at Inria, in Rennes, France, and head of the Inria research team “Hybrid” (25 people). He focuses on advanced 3D user interfaces, virtual reality (VR), 3D displays and brain-computer interfaces (BCIs). Anatole is or was involved as coordinator or principal investigator in numerous national or international collaborative projects, and serves as an expert on VR and BCI for the European Commission, the European Research Council and the French National Research Agency. He is the (co) author of more than 90 papers.

Investors

Since inception Mensia has raised EUR 10 million through equity, debt, grants, and non-dilutive financings.

Newrofeed

Newrofeed is a Horizon 2020-supported non-inferiority ADHD study, comparing Mensia Koala with the reference drug methylphenidate/Ritalin.

IT-Translation

IT-Translation is an investor and co-founder of digital technology start-ups, spun off from both public and private research.